JP2002517451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517451A5 JP2002517451A5 JP2000553084A JP2000553084A JP2002517451A5 JP 2002517451 A5 JP2002517451 A5 JP 2002517451A5 JP 2000553084 A JP2000553084 A JP 2000553084A JP 2000553084 A JP2000553084 A JP 2000553084A JP 2002517451 A5 JP2002517451 A5 JP 2002517451A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98110433.4 | 1998-06-08 | ||
EP98110433 | 1998-06-08 | ||
PCT/EP1999/003746 WO1999064016A1 (en) | 1998-06-08 | 1999-05-29 | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006025756A Division JP2006160759A (ja) | 1998-06-08 | 2006-02-02 | 慢性C型肝炎の処置のためのPeg−IFN−アルファ及びリバビリンの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002517451A JP2002517451A (ja) | 2002-06-18 |
JP2002517451A5 true JP2002517451A5 (ja) | 2005-12-22 |
JP3839667B2 JP3839667B2 (ja) | 2006-11-01 |
Family
ID=8232086
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000553084A Expired - Lifetime JP3839667B2 (ja) | 1998-06-08 | 1999-05-29 | 慢性C型肝炎の処置のためのPeg−INF−アルファ及びリバビリンの使用 |
JP2006025756A Pending JP2006160759A (ja) | 1998-06-08 | 2006-02-02 | 慢性C型肝炎の処置のためのPeg−IFN−アルファ及びリバビリンの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006025756A Pending JP2006160759A (ja) | 1998-06-08 | 2006-02-02 | 慢性C型肝炎の処置のためのPeg−IFN−アルファ及びリバビリンの使用 |
Country Status (35)
Country | Link |
---|---|
US (3) | US20030053986A1 (ja) |
EP (1) | EP1087778B1 (ja) |
JP (2) | JP3839667B2 (ja) |
KR (2) | KR20050055053A (ja) |
CN (1) | CN1170543C (ja) |
AR (1) | AR019855A1 (ja) |
AT (1) | ATE307597T1 (ja) |
AU (1) | AU767131B2 (ja) |
BR (1) | BR9911076A (ja) |
CA (1) | CA2334267C (ja) |
CL (1) | CL2010000828A1 (ja) |
CO (1) | CO5050297A1 (ja) |
CZ (1) | CZ298681B6 (ja) |
DE (1) | DE69927971T2 (ja) |
DK (1) | DK1087778T3 (ja) |
ES (1) | ES2251196T3 (ja) |
HK (1) | HK1037981A1 (ja) |
HR (1) | HRP20000808A2 (ja) |
HU (1) | HU228218B1 (ja) |
ID (1) | ID29285A (ja) |
IL (2) | IL139786A0 (ja) |
MA (1) | MA26641A1 (ja) |
MY (1) | MY124091A (ja) |
NO (1) | NO325598B1 (ja) |
NZ (1) | NZ508249A (ja) |
PE (1) | PE20000560A1 (ja) |
PL (1) | PL192364B1 (ja) |
RS (1) | RS50144B (ja) |
RU (1) | RU2271217C2 (ja) |
SA (1) | SA99200208B1 (ja) |
SI (1) | SI1087778T1 (ja) |
TR (1) | TR200003635T2 (ja) |
TW (1) | TWI241913B (ja) |
WO (1) | WO1999064016A1 (ja) |
ZA (1) | ZA200006814B (ja) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2251196T3 (es) * | 1998-06-08 | 2006-04-16 | F. Hoffmann-La Roche Ag | Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica. |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
IL154299A0 (en) * | 2000-08-07 | 2003-09-17 | Sciclone Pharmaceuticals Inc | Treatment of hepatitis c with thymosin, interferon and ribavirin |
US7179791B2 (en) * | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
KR100480429B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체 |
MXPA04012709A (es) | 2002-06-28 | 2005-09-30 | Idenix Cayman Ltd | Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae. |
NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
JP2005533824A (ja) * | 2002-06-28 | 2005-11-10 | イデニクス(ケイマン)リミテツド | フラビウイルス科感染の治療のための2’−c−メチル−3’−o−l−バリンエステルリボフラノシルシチジン |
WO2004046331A2 (en) | 2002-11-15 | 2004-06-03 | Idenix (Cayman) Limited | 2’-branched nucleosides and flaviviridae mutation |
WO2004052899A2 (en) * | 2002-12-12 | 2004-06-24 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
AU2003300434A1 (en) * | 2002-12-23 | 2004-07-22 | Idenix (Cayman) Limited | Process for the production of 3'-nucleoside prodrugs |
WO2005003147A2 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US8615282B2 (en) | 2004-07-13 | 2013-12-24 | Dexcom, Inc. | Analyte sensor |
WO2006000922A2 (en) * | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
EP1809301B1 (en) | 2004-09-14 | 2019-11-06 | Gilead Pharmasset LLC | 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates |
EP1814988A2 (en) | 2004-11-26 | 2007-08-08 | Pieris AG | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
EP1917037A2 (en) * | 2005-08-15 | 2008-05-07 | F.Hoffmann-La Roche Ag | Peg-ifn alpha and ribavirin for hbv treatment |
US9201979B2 (en) * | 2005-09-14 | 2015-12-01 | Millennial Media, Inc. | Syndication of a behavioral profile associated with an availability condition using a monetization platform |
US7781576B2 (en) * | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
AU2009264214B2 (en) | 2008-06-24 | 2013-06-06 | Technische Universitaet Muenchen | Muteins of hNGAL and related proteins with affinity for a given target |
WO2010033443A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
EP3222628A1 (en) | 2008-12-23 | 2017-09-27 | Gilead Pharmasset LLC | Nucleoside phosphoramidates |
US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
US8716012B2 (en) | 2009-05-08 | 2014-05-06 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
RU2012107812A (ru) | 2009-08-05 | 2013-09-10 | Аллерган, Инк. | Препараты мутеинов липокалинов с контролируемым высвобождением |
CN102596201A (zh) | 2009-10-30 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案 |
SG10201408073XA (en) | 2009-12-07 | 2015-01-29 | Pieris Ag | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
PT3290428T (pt) | 2010-03-31 | 2021-12-27 | Gilead Pharmasset Llc | Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino |
PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
EP2606061B8 (en) | 2010-08-16 | 2017-09-27 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
AU2011331232B2 (en) | 2010-11-15 | 2015-05-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
WO2012072806A1 (en) | 2010-12-02 | 2012-06-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for ctla-4 |
ME03009B (me) | 2011-09-16 | 2018-10-20 | Gilead Pharmasset Llc | Metode za lecenje hcv-a |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CA2858962C (en) | 2011-12-13 | 2023-09-05 | Pieris Ag | Compositions of human tear lipocalin muteins and methods of use thereof |
US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
US20140039923A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for receiving and managing patient data gathered during patient treatments |
US10526384B2 (en) | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
JP2015508418A (ja) | 2013-01-31 | 2015-03-19 | ギリアド ファーマセット エルエルシー | 2種の抗ウイルス化合物のコンビナトリアル製剤 |
US9150629B2 (en) | 2013-03-14 | 2015-10-06 | Daiichi Sankyo Co., Ltd. | Human tear lipocalins which bind PCSK9 and methods of use thereof |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
CN106573964B (zh) | 2014-05-22 | 2021-07-16 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
BR112017015773A2 (pt) | 2015-01-28 | 2018-03-27 | Pieris Pharmaceuticals Gmbh | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo |
MA41072A1 (fr) | 2015-02-18 | 2018-10-31 | Sanofi Sa | Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline |
SG11201708334RA (en) | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
MX2017014716A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Polipeptido de fusion anti-cancer. |
CA2982034A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
MX2018000447A (es) | 2015-07-15 | 2018-08-15 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas especificas para lag-3. |
JP2019505565A (ja) | 2015-11-30 | 2019-02-28 | ピエリス オーストラリア プロプライエタリー リミテッド | 新規の抗血管新生融合ポリペプチド |
TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
US11168119B2 (en) | 2017-01-18 | 2021-11-09 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for LAG-3 |
TWI837156B (zh) | 2018-07-31 | 2024-04-01 | 德商皮里斯製藥有限公司 | 新穎的cd137及pd-l1特異性融合蛋白 |
MX2021010039A (es) | 2019-02-26 | 2021-09-21 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas de fusion especificas para cd137 y gpc3. |
WO2021245240A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
BR112023020859A2 (pt) | 2021-04-08 | 2023-12-12 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina específicas para fator de crescimento do tecido conjuntivo (ctgf) |
WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
WO2024064713A1 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4681848A (en) * | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
DE3719046A1 (de) * | 1987-06-06 | 1988-12-15 | Basf Ag | Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5238915A (en) * | 1991-02-08 | 1993-08-24 | Wakunaga Seiyaku K.K. | Aromatic composition and method for controlling aroma |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
EP0730470B1 (en) * | 1993-11-10 | 2002-03-27 | Enzon, Inc. | Improved interferon polymer conjugates |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
US5695760A (en) * | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
WO1997016204A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
ES2251196T3 (es) * | 1998-06-08 | 2006-04-16 | F. Hoffmann-La Roche Ag | Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica. |
-
1999
- 1999-05-29 ES ES99927804T patent/ES2251196T3/es not_active Expired - Lifetime
- 1999-05-29 JP JP2000553084A patent/JP3839667B2/ja not_active Expired - Lifetime
- 1999-05-29 WO PCT/EP1999/003746 patent/WO1999064016A1/en active IP Right Grant
- 1999-05-29 SI SI9930843T patent/SI1087778T1/sl unknown
- 1999-05-29 TR TR2000/03635T patent/TR200003635T2/xx unknown
- 1999-05-29 DE DE69927971T patent/DE69927971T2/de not_active Expired - Lifetime
- 1999-05-29 RU RU2003119460/14A patent/RU2271217C2/ru active
- 1999-05-29 AU AU45033/99A patent/AU767131B2/en not_active Expired
- 1999-05-29 HU HU0102033A patent/HU228218B1/hu unknown
- 1999-05-29 EP EP99927804A patent/EP1087778B1/en not_active Expired - Lifetime
- 1999-05-29 IL IL13978699A patent/IL139786A0/xx active IP Right Grant
- 1999-05-29 KR KR1020057009098A patent/KR20050055053A/ko not_active Application Discontinuation
- 1999-05-29 CZ CZ20004487A patent/CZ298681B6/cs not_active IP Right Cessation
- 1999-05-29 DK DK99927804T patent/DK1087778T3/da active
- 1999-05-29 ID IDW20002551A patent/ID29285A/id unknown
- 1999-05-29 CN CNB998071706A patent/CN1170543C/zh not_active Expired - Lifetime
- 1999-05-29 BR BR9911076-8A patent/BR9911076A/pt not_active Application Discontinuation
- 1999-05-29 RS YUP-770/00A patent/RS50144B/sr unknown
- 1999-05-29 AT AT99927804T patent/ATE307597T1/de active
- 1999-05-29 PL PL344794A patent/PL192364B1/pl unknown
- 1999-05-29 CA CA002334267A patent/CA2334267C/en not_active Expired - Lifetime
- 1999-05-29 KR KR1020007013843A patent/KR20010052622A/ko active Search and Examination
- 1999-05-29 NZ NZ508249A patent/NZ508249A/xx not_active IP Right Cessation
- 1999-06-02 SA SA99200208A patent/SA99200208B1/ar unknown
- 1999-06-04 TW TW088109246A patent/TWI241913B/zh not_active IP Right Cessation
- 1999-06-04 CO CO99035303A patent/CO5050297A1/es unknown
- 1999-06-04 AR ARP990102664A patent/AR019855A1/es not_active Application Discontinuation
- 1999-06-04 PE PE1999000478A patent/PE20000560A1/es not_active Application Discontinuation
- 1999-06-07 MY MYPI99002297A patent/MY124091A/en unknown
- 1999-06-08 MA MA25613A patent/MA26641A1/fr unknown
-
2000
- 2000-11-20 IL IL139786A patent/IL139786A/en not_active IP Right Cessation
- 2000-11-21 ZA ZA200006814A patent/ZA200006814B/en unknown
- 2000-11-24 HR HR20000808A patent/HRP20000808A2/hr not_active Application Discontinuation
- 2000-12-05 NO NO20006178A patent/NO325598B1/no not_active IP Right Cessation
-
2001
- 2001-11-07 US US10/037,064 patent/US20030053986A1/en not_active Abandoned
- 2001-12-20 HK HK01108946A patent/HK1037981A1/xx not_active IP Right Cessation
-
2004
- 2004-07-26 US US10/899,726 patent/US20050031589A1/en not_active Abandoned
-
2006
- 2006-02-02 JP JP2006025756A patent/JP2006160759A/ja active Pending
-
2007
- 2007-01-24 US US11/657,287 patent/US20070196385A1/en not_active Abandoned
-
2010
- 2010-08-04 CL CL2010000828A patent/CL2010000828A1/es unknown